Key Strategic Consultants

Key Strategic Consultants

  • Pamela M. Williamson, RAC, FRAPS
    Regulatory Consultant

    Pamela Williamson, RAC, FRAPS, joins Acer with over 30 years of experience in regulatory affairs, quality assurance and compliance, pharmacovigilance, clinical and product development and manufacturing operations with the biopharmaceutical industry. Prior to joining Acer, Pam was senior vice president of global regulatory affairs and patient safety at Alexion Pharmaceuticals where she was responsible for […]

  • Philip T. Sager, M.D., FACC, FAHA, FHRS.
    Clinical Consultant

    Dr. Sager is an Adjunct Professor of Medicine at the Stanford University School of Medicine, the previous chair of the FDA Cardiovascular and Renal Drugs Advisory Committee, and an Executive Committee member of the FDA-Sponsored Cardiac Safety Research Consortium. He has played a major leadership role in CV safety issues in drug development. Dr. Sager […]

  • Richard Ridgewell, Ph.D.
    Nonclinical Development Consultant

    As Founder and Principal Consultant at Ridgewell Consulting, LLC, Dr. Ridgewell is responsible for guiding clients with strategic direction and development plan execution for the nonclinical aspects of drug development programs. He provides consultation focused on scientific and regulatory aspects of nonclinical drug development across the disciplines of pharmacology, toxicology and drug metabolism and pharmacokinetics. […]

  • Joff Masukawa
    Commercial Consultant

    Mr. Masukawa is President and founder of Diligentia, LLC, a life-sciences consultancy that develops commercial business strategies and tactical commercialization requirements for manufacturers of rare orphan and specialty drugs, cell and gene therapies, and other novel emerging medical innovations. Prior to founding Diligentia, Joff was Vice President and Global Head of Government Relations and Public […]

  • Christian Girard
    EU Business Operations Consultant

    Mr. Girard is the founder of Christian Girard E.I.R.L., d/b/a Orphan Drugs Industry Advisory & Intelligence with more than 20 years of domestic and cross-border industry and management consulting experience. He has extensive experience in operations, business development, funding and industry/patients organizations interactions in the rare diseases space. Mr. Girard is a frequent speaker at […]